Preliminary study of autologous bone marrow nucleated cells transplantation in children with spinal cord injury

Stem Cells Translational Medicine

Volumn 3, Issue 3, 2014, Pages 395-404

  Jarocha, Danuta ^a   Milczarek, Olga ^a   Kawecki, Zdzislaw ^a   Wendrychowicz, Anna ^a   Kwiatkowski, Stanislaw ^a   Majka, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Cell therapy; Cell transplantation; Spinal cord injury; Tissue regeneration; Transplantation

Indexed keywords

AMERICAN SPINAL INJURY ASSOCIATION IMPAIRMENT SCALE; ARTICLE; BLADDER FUNCTION; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BRADYCARDIA; CELL SUSPENSION; CHILD; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LAMINECTOMY; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATORY DRIVE; RISK ASSESSMENT; SCHOOL CHILD; SPASTICITY; SPINAL CORD INDEPENDENCE MEASURE SCALE; SPINAL CORD INJURY; SWALLOWING; TH3 CELL;

CELL THERAPY; CELL TRANSPLANTATION; SPINAL CORD INJURY; TISSUE REGENERATION; TRANSPLANTATION;

BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL- AND TISSUE-BASED THERAPY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; ILIUM; INJECTIONS, INTRAVENOUS; INJECTIONS, SPINAL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NERVE REGENERATION; SPINAL CORD INJURIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84896283334     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0141     Document Type: Article

References (56)

1. Thuret S, Moon LDF, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006;7:628-643.
2. Devivo MJ. Epidemiology of traumatic spinal cord injury: Trends and future implications. Spinal Cord 2012;50:365-372.
3. Vaccaro AR, Daugherty RJ, Sheehan TP et al. Neurologic outcome of early versus late surgery for cervical spinal cord injury. Spine 1997;22:2609-2613.
4. McKinley WO, Jackson AB, Cardenas DD et al. Long-term medical complications after traumatic spinal cord injury: A regional model systems analysis. Arch Phys Med Rehabil 1999;80:1402-1410.
5. Rekand T, Hagen EM, Grønning M. Spasticity following spinal cord injury. Tidsskr Nor Laegeforen 2012;132:970-973.
6. Norrbrink C, Löfgren M, Hunter JP et al. Patients' perspectives on pain. Top Spinal Cord Inj Rehabil 2012;18:50-56.
7. Hollis ER II., Lu P, Blesch A et al. IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury. Exp Neurol 2009;215:53-59.
8. Grill R, Murai K, Blesch A et al. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J Neurosci 1997;17: 5560-5572.
9. Novikova LN, Novikov LN, Kellerth J-O. Biopolymers and biodegradable smart implants for tissue regeneration after spinal cord injury. Curr Opin Neurol 2003;16:711-715.
10. Neumann S, Woolf CJ. Regeneration of dorsal column fibers into and beyond the lesion site following adult spinal cord injury. Neuron 1999;23:83-91.
11. Neumann S, Bradke F, Tessier-LavigneM et al. Regeneration of sensory axons within the injured spinal cord induced by intraganglionic cAMP elevation. Neuron 2002;34:885-893.
12. Qiu J, Cai D, DaiHet al. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron 2002;34:895-903.
13. Lu P, Yang H, Jones LL et al. Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. J Neurosci 2004;24:6402-6409.
14. Nikulina E, Tidwell JL, Dai HN et al. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci USA 2004;101:8786-8790.
15. Pearse DD, Pereira FC, Marcillo AE et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med 2004;10:610-616.
16. Bradbury EJ, Moon LDF, Popat RJ et al. ChondroitinaseABCpromotes functional recovery after spinal cord injury. Nature 2002;416: 636-640.
17. Freund P, Wannier T, Schmidlin E et al. Anti-Nogo-Aantibodytreatmentenhances sproutingof corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 2007;502:644-659.
18. Li J, Lepski G. Cell transplantation for spinal cord injury: A systematic review. Biomed Res Int 2013;786475.
19. Civin CI, Strauss LC, Brovall C et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133:157-165.
20. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: Characteristics and clinical applications. Folia Histochem Cytobiol 2006;44: 215-230.
21. Kucia M, Zhang YP, Reca R et al. Cells enriched in markers of neural tissuecommitted stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia 2006;20:18-28.
22. Majka M, Janowska-Wieczorek A, Ratajczak J et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34 (+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood 2001; 97:3075-3085.
23. Taguchi A, SomaT, TanakaHet al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004;114:330-338.
24. Shyu W-C, Lin S-Z, Chiang M-F et al. Intracerebral peripheral blood stem cell (CD34+) implantation induces neuroplasticity by enhancing beta1 integrin-mediated angiogenesis in chronic stroke rats. J Neurosci 2006;26: 3444-3453.
25. Zhao L-R, Duan W-M, Reyes M et al. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002;174:11-20.
26. Shen LH, Li Y, Chen J et al. Intracarotid transplantation of bone marrow stromal cells increases axon-myelin remodeling after stroke. Neuroscience 2006;137:393-399.
27. Akiyama Y, Radtke C, Honmou O et al. Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 2002;39:229-236.
28. Sasaki M, Honmou O, Akiyama Y et al. Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia 2001;35:26-34.
29. Chopp M, Zhang XH, Li Y et al. Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation. Neuroreport 2000;11: 3001-3005.
30. Park HC, ShimYS, Ha Y et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng 2005;11:913-922.
31. Deda H, Inci MC, Kürekçi AE et al. Treatment of chronic spinal cord injured patients with autologousbonemarrow-derived hematopoietic stem cell transplantation: 1-year followup. Cytotherapy 2008;10:565-574.
32. Geffner LF, Santacruz P, Izurieta M et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: Comprehensive case studies. Cell Transplant 2008;17:1277-1293.
33. Attar A, Ayten M, OzdemirMet al. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy 2011;13:54-60.
34. Syková E, Homola A, Mazanec R et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006;15:675-687.
35. Yoon SH, Shim YS, ParkYH et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. STEM CELLS 2007;25:2066-2073.
36. Callera F, do Nascimento RX. Delivery of autologous bone marrow precursor cells into the spinal cord via lumbar puncture technique in patients with spinal cord injury: A preliminary safety study. Exp Hematol 2006;34:130-131.
37. Kumar AA, Kumar SR, Narayanan R et al. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: A phase I/II clinical safety and primary efficacy data. Exp Clin Transplant 2009;7:241-248.
38. Chernykh ER, Stupak VV, Muradov GM et al. Application of autologous bone marrow stem cells in the therapy of spinal cord injury patients. Bull Exp Biol Med 2007;143:543-547.
39. Saito F, Nakatani T, Iwase M et al. Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: The first clinical trial case report. J Trauma 2008; 64:53-59.
40. Pal R, Venkataramana NK, Bansal A et al. Ex vivo-expanded autologous bone marrowderived mesenchymal stromal cells in human spinal cord injury/paraplegia: A pilot clinical study. Cytotherapy 2009;11:897-911.
41. Park JH, Kim DY, Sung IY et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery 2012;70:1238-1247; discussion 1247.
42. Karamouzian S, Nematollahi-Mahani SN, Nakhaee N et al. Clinical safety and primary efficacy of bone marrowmesenchymal cell transplantation in subacute spinal cord injuredpatients. Clin Neurol Neurosurg 2012;114:935-939.
43. Liu J, Han D, Wang Z et al. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells. Cytotherapy 2013;15:185-191.
44. KangK-S, KimSW, OhYHetal. A37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: A case study. Cytotherapy 2005;7: 368-373.
45. Ichim TE, Solano F, Lara F et al. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: A case report. Int Arch Med 2010;3:30.
46. Huang H, Xi H, Chen L et al. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant 2012;21(suppl 1): S23-S31.
47. Rao Y, Zhu W, Liu H et al. Clinical application of olfactory ensheathing cells in the treatment of spinal cord injury. J Int Med Res 2013; 41:473-481.
48. Chhabra HS, Lima C, Sachdeva S et al. Autologous olfactory [corrected] mucosal transplant in chronic spinal cord injury: An Indian Pilot Study. Spinal Cord 2009;47:887-895.
49. Lima C, Escada P, Pratas-Vital J et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair 2010;24:10-22.
50. Saberi H, Firouzi M, Habibi Z et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases. J Neurosurg Spine 2011;15:515-525.
51. Zhou XH, Ning GZ, Feng SQ et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: Six cases, more than five years of follow-up. Cell Transplant 2012;21(suppl 1):S39-S47.
52. Yazdani SO, Hafizi M, Zali A-R et al. Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. Cytotherapy 2013;15:782-791.
53. Moviglia GA, Fernandez Vina R, Brizuela JA et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006;8:202-209.
54. Anderson K, Aito S, Atkins M et al. Functional recovery measures for spinal cord injury: An evidence-based review for clinical practice and research. Report of the National Institute on Disability and Rehabilitation Research Spinal Cord Injury Measures Meeting. J Spinal Cord Med 2008;31:133-144.
55. Huang P, Li S, Han M et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005;28:2155-2160.
56. Yoshikawa T, Mitsuno H, Nonaka I et al. Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 2008;121: 860-877.